Navigation Links
Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc.

WALTHAM, Mass., Oct. 7 /PRNewswire/ -- Nova Biomedical Corporation, a leading developer of whole blood analyzers, today announced that the company's independent, wholly owned subsidiary, Sanvita CBGM, LLC, has completed the acquisition of certain assets of Sanvita, Inc., a subsidiary of CCS Medical, Inc.

Nova Biomedical is the sole manufacturer, and through this transaction, Nova's Consumer Blood Glucose Monitoring (CBGM) subsidiary has become the exclusive distributor, of the "NovaMax" consumer blood glucose product line in the United States. The NovaMax blood glucose monitor has the fastest test time and absolutely no coding.

"We are excited to have completed the highly complementary acquisition of these assets of Sanvita, Inc., which allows our CBGM subsidiary to assume full control of the distribution of our NovaMax brand," said Francis C. Manganaro, President and Chief Executive Officer of Nova Biomedical. "We are confident that this transaction better positions Nova Biomedical and Sanvita CBGM to streamline the development and delivery of NovaMax products for the benefit of customers. Together with the recent success of Nova Biomedical's hospital glucose monitor business, StatStrip, the company is better positioned to further improve its overall glucose monitoring business. We also look forward to continuing our partnership with CCS Medical and to a seamless integration of the NovaMax distribution business into Sanvita CBGM."

Additional information regarding the transaction has been filed with the United States Bankruptcy Court for the District of Delaware and can be found at the Court's website,

About Sanvita CBGM, LLC

Sanvita CBGM, LLC is an independent, wholly owned subsidiary of Nova Biomedical and the exclusive distributor of NovaMax products in the United States.

About Nova Biomedical

Nova Biomedical is a world leader in the development of whole blood analyzers to support the care of home based and hospitalized patients. Based upon innovative biosensor technology, Nova glucose monitors are designed for rapid and accurate measurement of patient glucose levels without coding test strips. Nova Biomedical has pioneered many advances in glucose testing and introduced its first glucose whole blood biosensor to hospitals in 1987.


For Nova Biomedical:

    John C. Swan
    Nova Biomedical Corporation

SOURCE Nova Biomedical Corporation

SOURCE Nova Biomedical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Places and People - Truphatek opens USA subsidiary
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
5. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
6. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
7. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
8. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
9. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
10. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
11. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
Post Your Comments:
(Date:12/1/2015)... During the recent 2015 Transcatheter Cardiovascular ... CA , Medinol Ltd. continued to introduce ... a satellite symposium, "The BioNIR eDES: The Role ... a renowned physician panel discussed the key attributes ... Stent System and the Medinol eDES Coronary Stent ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The workstation boundaries for ... IMAGE Information Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image ... 29 to December 4, 2015. , MED-TAB is expected to change teleradiology ...
(Date:12/1/2015)... ... , ... The importance of volumetric breast density assessment for ... abstracts accepted for presentation here, at the 101st Annual Radiology Society of North ... of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging and ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free ... in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, ... organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) ... exceptional special needs providers that excel in synthesizing the areas of clinical quality, ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
Breaking Medicine News(10 mins):